Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder, primarily characterized by a decrease in insulin secretion and typically accompanied by insulin resistance. When untreated, T2DM is leading to an inevitable long-term complication. However, the novel treatment of T2DM like for example...
Saved in:
Main Authors: | Mariya Kalinkova (Author), Tanya Kadiyska (Author), Teodora Handjieva-Darlenska (Author) |
---|---|
Format: | Book |
Published: |
Pensoft Publishers,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017) -
Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024) -
Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015) -
Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020) -
Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
by: Olusola F. Onoviran, et al.
Published: (2019)